Egenesis

Cambridge, MA · Founded 2015 · Privately Held (backing)

Developer of human-compatible engineered organs and cells designed to address the global shortage of transplantable organs. Egenesis is based in Cambridge, MA and was founded in 2015. Its last known valuation is $330 million. It has raised $454 million across 5 recorded rounds; the latest was a $25.4 million debt round in Feb 2024.

Last price · $/share
—
Implied valuation
$330.0M
Total raised
$454.0M
Last round
Debt
Feb 2024

Who backs Egenesis?

37 investors
InvestorType
Khosla VenturesVenture capital
Lux CapitalVenture capital
Alexandria Venture InvestmentsOther
ARCH Venture PartnersVenture capital
Catalio Capital ManagementVenture capital
b2ventureVenture capital
Polaris PartnersVenture capital
The Invus GroupPE / buyout
Osage University PartnersVenture capital
Samsara BioCapitalVenture capital
+ 27 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Egenesis investors

37 investors are on record for Egenesis, including Khosla Ventures, Lux Capital, Alexandria Venture Investments and ARCH Venture Partners. By type, the record holds 11 venture capital firms and 3 hedge funds. The debt round in Feb 2024 drew 11 investors.

Free account
More of Egenesis with a free account
  • ·The complete investor list: 37 names
  • ·Watch Egenesis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 37 firms already write checks for companies like Egenesis. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View